Aallstate(ALL)
Search documents
Aallstate(ALL) - 2024 Q2 - Quarterly Results
2024-07-31 20:15
Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: | --- | --- | |-----------------|--------------------| | Nick Nottoli | Allister Gobin | | Media Relations | Investor Relations | | (847) 402-5600 | (847) 402-2800 | Allstate Reports Second Quarter 2024 Results Operational execution delivers strong underlying results NORTHBROOK, Ill., July 31, 2024 – The Allstate Corporation (NYSE: ALL) today reported financial results for the second quarter of 2024. The Allstate Corporation Consolidated Highlights | --- | --- | ...
Can Allstate (ALL) Q2 Earnings Beat Estimates on Premium Growth?
ZACKS· 2024-07-30 18:15
The Allstate Corporation (ALL) is set to report its second-quarter 2024 results on Jul 31, after the closing bell.The Zacks Consensus Estimate for second-quarter earnings is currently pegged at 33 cents per share, implying an improvement of 107.5% from the year-ago reported number. The estimate remained stable over the past week. The Zacks Consensus Estimate for second-quarter revenues is currently pegged at $15.6 billion, suggesting a 10.1% rise from the year-ago actuals. Image Source: Zacks Investment Res ...
Ahead of Allstate (ALL) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
ZACKS· 2024-07-26 14:20
Analysts on Wall Street project that Allstate (ALL) will announce quarterly earnings of $0.33 per share in its forthcoming report, representing an increase of 107.5% year over year. Revenues are projected to reach $15.55 billion, increasing 10.1% from the same quarter last year.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this perio ...
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
GlobeNewswire News Room· 2024-07-25 20:30
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated1There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transplantation (HSCT) or relapse afterFDA ODD and RPDD designations for UCART22 marks an important step towards developing allogeneic CAR T products that would be readily available for all patients NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- C ...
Here's Why Allstate (ALL) Gained But Lagged the Market Today
ZACKS· 2024-07-22 22:55
In the latest trading session, Allstate (ALL) closed at $174.83, marking a +0.26% move from the previous day. This move lagged the S&P 500's daily gain of 1.08%. At the same time, the Dow added 0.32%, and the tech-heavy Nasdaq gained 1.58%.Prior to today's trading, shares of the insurer had gained 8.64% over the past month. This has outpaced the Finance sector's loss of 2.72% and the S&P 500's gain of 0.43% in that time.Market participants will be closely following the financial results of Allstate in its u ...
Allstate (ALL) Rises Higher Than Market: Key Facts
ZACKS· 2024-07-15 22:56
The most recent trading session ended with Allstate (ALL) standing at $166.91, reflecting a +1.97% shift from the previouse trading day's closing. The stock outperformed the S&P 500, which registered a daily gain of 0.28%. At the same time, the Dow added 0.53%, and the tech-heavy Nasdaq gained 0.4%.Shares of the insurer witnessed a gain of 4.21% over the previous month, beating the performance of the Finance sector with its loss of 2.84% and the S&P 500's gain of 3.78%.The investment community will be close ...
Allstate (ALL) Outperforms Broader Market: What You Need to Know
ZACKS· 2024-07-08 22:56
Allstate (ALL) closed the most recent trading day at $159.54, moving +0.7% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.1%. At the same time, the Dow lost 0.08%, and the tech-heavy Nasdaq gained 0.28%.Shares of the insurer have depreciated by 4.02% over the course of the past month, underperforming the Finance sector's gain of 1.14% and the S&P 500's gain of 4.08%.The investment community will be paying close attention to the earnings performance ...
Allstate (ALL) Increases Despite Market Slip: Here's What You Need to Know
ZACKS· 2024-06-24 22:55
In the latest trading session, Allstate (ALL) closed at $162.41, marking a +1.18% move from the previous day. This move outpaced the S&P 500's daily loss of 0.31%. At the same time, the Dow added 0.67%, and the tech-heavy Nasdaq lost 1.09%.The insurer's shares have seen a decrease of 2.63% over the last month, not keeping up with the Finance sector's loss of 1.77% and the S&P 500's gain of 2.73%.The investment community will be closely monitoring the performance of Allstate in its forthcoming earnings repor ...
Allstate (ALL) Could Be a Great Choice
ZACKS· 2024-06-24 16:50
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that ...
Wall Street Analysts Think Allstate (ALL) Is a Good Investment: Is It?
ZACKS· 2024-06-18 14:31
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Allstate (ALL) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Allstate currently has an average brokerage recommendation (ABR) ...